IL144003A0 - Compounds and methods for modulation of estrogen receptors - Google Patents
Compounds and methods for modulation of estrogen receptorsInfo
- Publication number
- IL144003A0 IL144003A0 IL14400399A IL14400399A IL144003A0 IL 144003 A0 IL144003 A0 IL 144003A0 IL 14400399 A IL14400399 A IL 14400399A IL 14400399 A IL14400399 A IL 14400399A IL 144003 A0 IL144003 A0 IL 144003A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- disclosed
- compounds
- same
- modulation
- Prior art date
Links
- 102000015694 estrogen receptors Human genes 0.000 title abstract 4
- 108010038795 estrogen receptors Proteins 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000033830 Hot Flashes Diseases 0.000 abstract 1
- 206010060800 Hot flush Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 206010027951 Mood swings Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 239000003256 environmental substance Substances 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 201000004240 prostatic hypertrophy Diseases 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 210000004291 uterus Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11447298P | 1998-12-30 | 1998-12-30 | |
| PCT/US1999/031290 WO2000039120A2 (en) | 1998-12-30 | 1999-12-30 | Compounds and methods for modulation of estrogen receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL144003A0 true IL144003A0 (en) | 2002-04-21 |
Family
ID=22355427
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14400399A IL144003A0 (en) | 1998-12-30 | 1999-12-30 | Compounds and methods for modulation of estrogen receptors |
| IL144003A IL144003A (en) | 1998-12-30 | 2001-06-26 | History of 3 - phenyl - 4 - [(heterocyclic) ethoxy] - benzyl - coumarin - 7 - metamorphoses and pharmaceutical preparations containing these compounds to regulate estrogen receptors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL144003A IL144003A (en) | 1998-12-30 | 2001-06-26 | History of 3 - phenyl - 4 - [(heterocyclic) ethoxy] - benzyl - coumarin - 7 - metamorphoses and pharmaceutical preparations containing these compounds to regulate estrogen receptors |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1140889B1 (enExample) |
| JP (1) | JP2002533456A (enExample) |
| KR (1) | KR100615757B1 (enExample) |
| CN (2) | CN1155589C (enExample) |
| AT (1) | ATE248157T1 (enExample) |
| AU (1) | AU765159B2 (enExample) |
| CA (1) | CA2356986A1 (enExample) |
| DE (1) | DE69910830T2 (enExample) |
| DK (1) | DK1140889T3 (enExample) |
| ES (1) | ES2207982T3 (enExample) |
| HK (1) | HK1041258B (enExample) |
| IL (2) | IL144003A0 (enExample) |
| PT (1) | PT1140889E (enExample) |
| WO (1) | WO2000039120A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6822563B2 (en) | 1997-09-22 | 2004-11-23 | Donnelly Corporation | Vehicle imaging system with accessory control |
| US5877897A (en) | 1993-02-26 | 1999-03-02 | Donnelly Corporation | Automatic rearview mirror, vehicle lighting control and vehicle interior monitoring system using a photosensor array |
| US7655894B2 (en) | 1996-03-25 | 2010-02-02 | Donnelly Corporation | Vehicular image sensing system |
| US6291456B1 (en) | 1998-12-30 | 2001-09-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6331562B1 (en) | 1998-12-30 | 2001-12-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6593322B1 (en) | 1999-03-17 | 2003-07-15 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| CA2367895A1 (en) | 1999-03-17 | 2000-09-21 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| AU781282B2 (en) * | 1999-12-30 | 2005-05-12 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| EP1177787A3 (en) * | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
| EP1281710A1 (en) * | 2001-08-03 | 2003-02-05 | CHIESI FARMACEUTICI S.p.A. | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| EP1229036B1 (en) * | 2001-01-24 | 2005-01-12 | CHIESI FARMACEUTICI S.p.A. | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| SK287086B6 (sk) * | 2001-01-24 | 2009-11-05 | Chiesi Farmaceutici S.P.A. | 2H-1-Benzopyránové deriváty, farmaceutické prostriedky s ich obsahom a ich použitie |
| CN100516059C (zh) * | 2001-04-10 | 2009-07-22 | 宝生物工程株式会社 | 治疗剂 |
| US7148252B2 (en) * | 2001-10-03 | 2006-12-12 | Signal Pharmaceuticals, Llc | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis |
| UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| AU2003239155B2 (en) * | 2002-04-19 | 2008-12-04 | Novartis Ag | Benzopyranone compounds, compositions thereof, and methods of treatment therewith |
| EP1504276B1 (en) | 2002-05-03 | 2012-08-08 | Donnelly Corporation | Object detection system for vehicle |
| US7091235B2 (en) | 2002-10-15 | 2006-08-15 | Signal Pharmaceuticals, Llc | Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer |
| FR2849653B1 (fr) * | 2003-01-08 | 2006-08-25 | B F B Etudes Et Rech S Experim | Derives de la coumarine ayant une affinite pour les recepteurs aux estrogenes, procede pour leur preparation et compositions pharmaceutiques en contenant |
| WO2005028472A1 (en) * | 2003-09-15 | 2005-03-31 | Signal Pharmaceuticals, Llc | Benzopyranone compounds, compositions thereof, and methods of treatment therewith |
| US7526103B2 (en) | 2004-04-15 | 2009-04-28 | Donnelly Corporation | Imaging system for vehicle |
| CN101146798A (zh) * | 2005-01-21 | 2008-03-19 | 詹森药业有限公司 | 用作雌激素受体调节剂的新的杂环苯并[c]色烯衍生物 |
| AU2006262190A1 (en) * | 2005-06-24 | 2007-01-04 | Signal Pharmaceuticals, Llc. | Benzopyranone compounds for treating cancer |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| EP1860104A1 (en) * | 2006-05-22 | 2007-11-28 | Aptanomics | Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof |
| CN101200460B (zh) * | 2007-11-19 | 2010-06-16 | 北京珅奥基医药科技有限公司 | 二氢苯并吡喃酮类化合物及其用途 |
| CN105541810B (zh) * | 2016-03-04 | 2019-05-17 | 南京工业大学 | 一种香豆素类nedd8激活酶抑制剂及其制备方法与应用 |
| CN105801543B (zh) * | 2016-04-18 | 2019-08-02 | 中国药科大学 | 4-芳香胺-香豆素衍生物及其制备方法和医药用途 |
| CN105801544A (zh) * | 2016-04-18 | 2016-07-27 | 中国药科大学 | 3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途 |
| CN112426420B (zh) * | 2020-12-01 | 2021-12-28 | 浙江大学 | 香豆素-二硫代氨基甲酸酯衍生物在制备抗肿瘤药物中的应用 |
| CN112645922B (zh) * | 2020-12-24 | 2022-01-07 | 中国人民解放军空军军医大学 | 香豆素类化合物、制备方法及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2857401A (en) * | 1956-12-20 | 1958-10-21 | Searle & Co | Acetylated coumarin derivatives |
| DE4323409A1 (de) * | 1993-07-13 | 1995-01-19 | Boehringer Mannheim Gmbh | Verwendung von Cumarinen und Carbostyrilen als PLA¶2¶-Inhibitoren, neue Cumarine und Carbostyrile, Verfahren zu ihrer Herstellung und Arzneimittel |
| YU6996A (sh) * | 1995-02-06 | 1999-03-04 | Eli Lilly And Company | Upotreba benzotiofena za dobijanje leka |
| CA2270113A1 (en) * | 1996-10-28 | 1998-05-07 | Poul Jacobsen | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| ES2188909T3 (es) * | 1996-10-28 | 2003-07-01 | Novo Nordisk As | Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os |
| ZA979644B (en) * | 1996-10-28 | 1998-04-28 | Novo Nordisk As | Heterocyclic compounds, compositions and uses. |
| EP0937059A1 (en) * | 1996-10-28 | 1999-08-25 | Novo Nordisk A/S | NOVEL $i(TRANS)-3,4-CHROMAN DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES |
| JP2001502708A (ja) * | 1996-10-28 | 2001-02-27 | ノボ ノルディスク アクティーゼルスカブ | エストロゲン関連の疾患または症候群の予防または治療に有用な新規なシス―３，４―クロマン誘導体 |
| WO1998018771A1 (en) * | 1996-10-28 | 1998-05-07 | Novo Nordisk A/S | Novel (-)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
-
1999
- 1999-12-30 AT AT99968578T patent/ATE248157T1/de not_active IP Right Cessation
- 1999-12-30 DK DK99968578T patent/DK1140889T3/da active
- 1999-12-30 ES ES99968578T patent/ES2207982T3/es not_active Expired - Lifetime
- 1999-12-30 CA CA002356986A patent/CA2356986A1/en not_active Abandoned
- 1999-12-30 PT PT99968578T patent/PT1140889E/pt unknown
- 1999-12-30 HK HK02101413.5A patent/HK1041258B/en not_active IP Right Cessation
- 1999-12-30 DE DE69910830T patent/DE69910830T2/de not_active Expired - Fee Related
- 1999-12-30 CN CNB998163740A patent/CN1155589C/zh not_active Expired - Fee Related
- 1999-12-30 EP EP99968578A patent/EP1140889B1/en not_active Expired - Lifetime
- 1999-12-30 WO PCT/US1999/031290 patent/WO2000039120A2/en not_active Ceased
- 1999-12-30 AU AU25970/00A patent/AU765159B2/en not_active Ceased
- 1999-12-30 CN CNB2004100422993A patent/CN100339374C/zh not_active Expired - Fee Related
- 1999-12-30 JP JP2000591031A patent/JP2002533456A/ja active Pending
- 1999-12-30 IL IL14400399A patent/IL144003A0/xx active IP Right Grant
- 1999-12-30 KR KR1020017008410A patent/KR100615757B1/ko not_active Expired - Fee Related
-
2001
- 2001-06-26 IL IL144003A patent/IL144003A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100615757B1 (ko) | 2006-08-25 |
| HK1075893A1 (zh) | 2005-12-30 |
| WO2000039120A2 (en) | 2000-07-06 |
| DE69910830D1 (de) | 2003-10-02 |
| IL144003A (en) | 2006-07-05 |
| EP1140889A2 (en) | 2001-10-10 |
| DK1140889T3 (da) | 2003-12-22 |
| HK1041258B (en) | 2003-12-12 |
| WO2000039120A3 (en) | 2000-10-26 |
| CA2356986A1 (en) | 2000-07-06 |
| PT1140889E (pt) | 2004-01-30 |
| CN1337958A (zh) | 2002-02-27 |
| CN1597677A (zh) | 2005-03-23 |
| KR20010101346A (ko) | 2001-11-14 |
| DE69910830T2 (de) | 2004-06-17 |
| ATE248157T1 (de) | 2003-09-15 |
| AU765159B2 (en) | 2003-09-11 |
| AU2597000A (en) | 2000-07-31 |
| CN1155589C (zh) | 2004-06-30 |
| ES2207982T3 (es) | 2004-06-01 |
| EP1140889B1 (en) | 2003-08-27 |
| HK1041258A1 (en) | 2002-07-05 |
| CN100339374C (zh) | 2007-09-26 |
| JP2002533456A (ja) | 2002-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL144003A0 (en) | Compounds and methods for modulation of estrogen receptors | |
| IL150463A0 (en) | Compounds and methods for modulation of estrogen receptors | |
| WO2000055137A8 (en) | Compounds and methods for modulation of estrogen receptors | |
| MY115784A (en) | Estrogen agonists/antagonists | |
| Orwoll et al. | Androgen receptors in osteoblast-like cell lines | |
| MY112949A (en) | Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia | |
| AU5467699A (en) | Substituted isoxazole as estrogen receptor modulators | |
| DE69838177D1 (de) | Androgensyntheseinhibitoren | |
| MY102294A (en) | Substituted androsta-1, 4-diene-3, 17-diones and process for their preparation | |
| NZ331941A (en) | Pentafluorobenzenesulfonamides and analogs and use in regulation of LDL receptor synthesis | |
| EA200300474A1 (ru) | Модуляторы рецепторов эстрогена | |
| DE69603827D1 (de) | Waisen-rezeptor | |
| Ben-Hur et al. | Localization of estrogen receptors in long bones and vertebrae of human fetuses | |
| Chakravatri et al. | Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer—results from a pilot study | |
| NO984631D0 (no) | <alfa>1-Adrenerge reseptor-antagonister | |
| PL336205A1 (en) | Method of treating and preventing prostatic carcinoma as well as benign prostatic hypertrophy using selective modulators of oestrogen receptors | |
| NO983724D0 (no) | 17-<beta>-syklopropyl (amino/oksi)-4-aza-steroider som aktive inhibitorer av testosteron-5-<alfa>-reduktase og C17-20-lylase | |
| Friedman | The Estradiol-Dihydrotestosterone model of prostate cancer | |
| Gupta et al. | Epidermal growth factor binding in the developing male reproductive duct and its regulation by testosterone | |
| Dorn | Hormones during embryogenesis of the milkweed bug, Oncopeltus fasciatus (Heteroptera: Lygaeidae) | |
| DK0898708T3 (da) | Interaktion af cyclin D1 og estrogenreceptor og anvendelse deraf i assays | |
| FUSE et al. | Changes in cytosolic androgen receptor after administration of testosterone of androgen-dependent mouse mammary tumor (Shionogi Carcinoma) and its sublines of altered androgen dependency | |
| ES2196264T3 (es) | Compuestos b nor-6-tiaequilenina 8-sustituidos que tienen actividad como moduladores selectivos de los receptores de estrogenos. | |
| DK1196428T3 (da) | 11-beta-aryl-17,17-spirothiolan-substituerede steroider | |
| MY137604A (en) | Benzopyranone compounds, compositions thereof, and methods of treatment therewith |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |